Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01170234|
Recruitment Status : Completed
First Posted : July 27, 2010
Last Update Posted : February 29, 2012
|Condition or disease||Intervention/treatment|
|Eosinophilic Esophagitis||Device: NIOX MINO® Airway Inflammation Monitor|
|Study Type :||Observational|
|Actual Enrollment :||14 participants|
|Official Title:||Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis|
|Study Start Date :||August 2010|
|Primary Completion Date :||February 2012|
|Study Completion Date :||February 2012|
Eosinophilic esophagitis (EoE)
Treatment-naïve EoE patients, age 7 -65
Device: NIOX MINO® Airway Inflammation Monitor
We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
- Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitis [ Time Frame: 2 years ]The objective of this study is to determine the feasibility of using exhaled nitric oxide (FeNO) as a noninvasive surrogate marker for EoE disease activity. We will measure FeNO levels on a group of patients with confirmed EoE before, during and after the course of topical corticosteroid therapy.
- Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitis [ Time Frame: 2 years ]Change in exhaled nitric oxide levels during corticosteroid treatment.
- Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitis [ Time Frame: 2 years ]Intra- and inter-patient variability in exhaled nitric oxide levels.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01170234
|United States, Massachusetts|
|Tufts Medical Center|
|Boston, Massachusetts, United States, 02111|
|Principal Investigator:||John Leung, MD||Tufts Medical Center|